MARC Record from marc_columbia

LEADER: 03524mam a2200349 a 4500
001 1853299
005 20220609011619.0
008 960903t19961996gw a b 001 0 eng d
020 $a3540610766
035 $a(OCoLC)ocm35335471
035 $9ALT8965CU
035 $a(NNC)1853299
035 $a1853299
040 $aGZM$cGZM$dOrLoB-B
245 00 $aAdeno-associated virus (AAV) vectors in gene therapy /$cedited by K.I. Berns and C. Giraud.
260 $aBerlin ;$aNew York :$bSpringer,$c[1996], ©1996.
300 $avi, 173 pages :$billustrations ;$c25 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aCurrent topics in microbiology and immunology,$x0070-217X ;$v218
504 $aIncludes bibliographical references and index.
505 00 $tBiology of Adeno-associated Virus /$rK. I. Berns and C. Giraud --$tThe Roles of AAV Rep Proteins in Gene Expression and Targeted Integration /$rJ. A. Chiorini, S. M. Wiener, L. Yang, R. H. Smith, B. Safer, N. P. Kilcoin, Y. Liu, E. Urcelay and R. M. Kotin --$tPackaging Systems for Adeno-associated Virus Vectors /$rJ. P. Trempe --$tThe Challenges of Recombinant Adeno-associated Virus Manufacturing: Alternative Use of Adeno-associated Virus Plasmid/Liposome Complexes for Gene Therapy Applications /$rJ. S. Lebkowski, T. B. Okarma and R. Philip --$tAdeno-associated Virus Vectors for Gene Therapy of the Hematopoietic System /$rS. Chatterjee and K. K. Wong, Jr. --$tAdeno-associated Virus Vectors for Gene Transfer into Erythroid Cells /$rD. M. McCarty and R. J. Samulski --$tAdeno-associated Virus 2-Mediated Transduction and Erythroid Lineage-Specific Expression in Human Hematopoietic Progenitor Cells /$rA. Srivastava, X.-S. Wang, S. Ponnazhagan, S. Z. Zhou and M. C. Yoder --
505 80 $tDevelopment of Adeno-associated Virus Vectors for Gene Therapy of Cystic Fibrosis /$rB. J. Carter and T. R. Flotte --$tAdeno-associated Virus-Based Vectors As Antivirals /$rK. K. Wong, Jr. and S. Chatterjee.
520 $aViral vectors have been the favored delivery vehicle for gene therapy in recent years. Adeno-associated virus has become a candidate of great interest because of its biological properties which include site specific integration in human chromosome 19.
520 8 $aThe subject of this book is the use of adeno-associated virus as a new viral vector for gene therapy. AAV vectors can be used to deliver foreign DNA to mammalian cells with the goal of curing genetic diseases and allied conditions. The non-pathogenicity and site specific integration of AAV via a non-homologous recombination event into human chromosome 19 make this virus a very attractive vector.
520 8 $aData from in vitro and in vivo experiments are presented and discussed including recent studies with hematopoietic stem cells and non-dividing cells. Various protocols for preparing recombinant AAV vectors and their intracellular delivery are also extensively discussed. The first trial of AAV as vector for human gene therapy was conducted in late 1995.
650 0 $aGene therapy.$0http://id.loc.gov/authorities/subjects/sh85053738
650 0 $aAdenoviruses.$0http://id.loc.gov/authorities/subjects/sh85000854
700 1 $aBerns, Kenneth I.,$d1938-$0http://id.loc.gov/authorities/names/n83069959
700 1 $aGiraud, Catherine.$0http://id.loc.gov/authorities/names/nr94025718
830 0 $aCurrent topics in microbiology and immunology ;$v218.$0http://id.loc.gov/authorities/names/n42036058
852 00 $boff,bio$hQR1$i.C83 v.218